GelSana Therapeutics, an Aurora, CO-based advanced wound care company, raised a new funding of undisclosed amount.
The round was led by Innosphere Ventures Fund with participation from Mines Venture Fund.
GelSana, which has secured $3.1M in both dilutive and non-dilutive funding, intends to use the funds to push its first product towards the clinical market and provide a solution for difficult-to-heal wounds.
What sets GelSana apart from its competitors is its revolutionary hydrogel technology, comprised of materials that promote anti-inflammatory effects and which are capable of controlled drug delivery. Additionally, GelSana’s elastic hydrogels have the unique ability to stretch and self-heal, making them ideal for various wound care applications.
Led by CEO Melissa Krebs, GelSana is advancing hydrogel technology, with its first product, Cleragel, towards FDA registration and early clinical use. Its patented hydrogel technology creates an anti-inflammatory environment and offers sustained drug delivery, reducing the need for repeated applications and making wound care more efficient and cost-effective.
GelSana has already made meaningful steps, including licensing IP from the Colorado School of Mines, completing key animal studies demonstrating the superior capability of their hydrogel to heal diabetic wounds, and securing multiple grants and awards for their innovative work.
FinSMEs
30/11/2023